|Dr. Jacqualyn A. Fouse||CEO & Director||1.27M||N/A||1961|
|Mr. Jonathan Biller J.D.||CFO and Head of Legal & Corp. Affairs||769.33k||N/A||1964|
|Dr. Bruce Car Ph.D.||Chief Scientific Officer||894.8k||N/A||1962|
|Dr. Christopher J. Bowden M.D.||Strategic Advisor||767.55k||825.41k||1961|
|Dr. Lewis Clayton Cantley||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1949|
|Dr. Tak Wah Mak||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1946|
|Dr. Craig B. Thompson||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||1953|
|Dr. Shin-San Su Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1956|
|Mr. T. J. Washburn Jr.||Principal Accounting Officer||N/A||N/A||1981|
|Dr. Clive Patience||Exec. VP of Technical Operations||N/A||N/A||1964|
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 7; Compensation: 8.